Atossa Therapeutics (NASDAQ:ATOS) Downgraded by StockNews.com to “Sell”

Atossa Therapeutics (NASDAQ:ATOS) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday.

Several other analysts also recently commented on ATOS. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a report on Wednesday, September 11th. HC Wainwright raised their price objective on shares of Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Atossa Therapeutics Stock Performance

NASDAQ:ATOS remained flat at $1.28 on Monday. The company’s stock had a trading volume of 722,207 shares, compared to its average volume of 1,076,344. The stock has a market cap of $161.03 million, a price-to-earnings ratio of -5.82 and a beta of 1.23. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.37. Atossa Therapeutics has a 1 year low of $0.67 and a 1 year high of $2.31.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors have recently bought and sold shares of ATOS. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics in the second quarter valued at approximately $29,000. Intech Investment Management LLC acquired a new stake in Atossa Therapeutics in the 3rd quarter valued at $29,000. SG Americas Securities LLC lifted its position in Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares in the last quarter. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics during the 1st quarter worth about $72,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics in the third quarter valued at about $75,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.